{"disease":{"id":"hepatocellular","name":"hepatocellular"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1789844","indication_name":"First-Line Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1946170","indication_name":"Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"REGORAFENIB","company_name":"","drug_phase":"marketed","molecular_target":"RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Regorafenib inhibits multiple kinases involved in oncogenesis, angiogenesis, metastasis, and tumor immunity."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"anti-ox40-antibody-pf-04518600","indication_name":"Hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-OX40 Antibody PF-04518600","generic_name":"anti-ox40-antibody-pf-04518600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"OX40 receptor","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pd-0332991","indication_name":"Advanced Hepatocellular Carcinoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"}],"offLabel":[],"totalMarketed":6,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT03706742","title":"STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":12386,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05355662","title":"Prognosis Analysis of Elderly Donor Liver in Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":11569,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06241326","title":"Immunotherapy for Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07153783","title":"Interventional AI-Human Collaboration for Liver Tumor Diagnosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":10333,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT06859840","title":"LEAF(Liver Tumor dEtection And classiFication AI)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03588442","title":"Prospective Surveillance for Very Early Hepatocellular Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT06061328","title":"Project OASIS: Optimizing Approaches to Select Implementation Strategies","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":8020,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07157085","title":"AI Multitask Model for HCC Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":7000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06084234","title":"National Liver Cancer Screening Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":5500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT04348838","title":"Prospective Cohort of Patients With Hepatocellular Carcinoma in France","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03612726","title":"The Overall Survival of Patients With Unresectable HCC in Real-life","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Humanity & Health Medical Group Limited","has_results":false},{"nct_id":"NCT05486572","title":"Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI","phase":"NA","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07010198","title":"Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City","phase":"","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"Zhongshan People's Hospital, Guangdong, China","has_results":false},{"nct_id":"NCT03047603","title":"Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC","phase":"","overall_status":"COMPLETED","enrollment_count":4005,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT05932719","title":"Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04160897","title":"Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Qing XIe","has_results":false},{"nct_id":"NCT03702998","title":"Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population","phase":"","overall_status":"COMPLETED","enrollment_count":3900,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06062706","title":"Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":3448,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06776185","title":"Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Chen Xiaoping","has_results":false},{"nct_id":"NCT04021056","title":"Observational Study on Patients With Hepatocellular Carcinoma (HCC)","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03756051","title":"Harms of Hepatocellular Carcinoma Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":2871,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02582918","title":"Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5","phase":"NA","overall_status":"COMPLETED","enrollment_count":2871,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT00341705","title":"The Second Multicenter Hemophilia Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2565,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03233360","title":"Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2533,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT05693519","title":"GastroIntestinal Cancer in Children and Adolescents","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Paul G. Kemps, MD","has_results":false},{"nct_id":"NCT05431621","title":"Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":2430,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04681274","title":"Phenotyping Liver Cancer Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2429,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05721300","title":"Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2215,"lead_sponsor_name":"Zhongshan Hospital (Xiamen), Fudan University","has_results":false},{"nct_id":"NCT03628651","title":"Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":2150,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT07298577","title":"Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT06233708","title":"Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":2092,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05520801","title":"Primary Hepatobiliary Cancer Cohort of Central China","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06405321","title":"Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Guangxi Medical University","has_results":false},{"nct_id":"NCT07038863","title":"Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07156617","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Xuhua Duan","has_results":false},{"nct_id":"NCT05420922","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT00913757","title":"A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area","phase":"","overall_status":"COMPLETED","enrollment_count":1871,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06156748","title":"CT Imaging for Guiding PA-TACE for HCC","phase":"","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT06799468","title":"Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":1769,"lead_sponsor_name":"European Hepatocellular Cancer Liver Transplant Group","has_results":false},{"nct_id":"NCT03232593","title":"A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)","phase":"","overall_status":"COMPLETED","enrollment_count":1758,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01933945","title":"Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":1676,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07091942","title":"Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05128123","title":"Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}